BRPI0919414A2 - Inibição da interação entre hif-1alfa e p300/cbp com hélices à base de substituintes de ligação de hidrogênio - Google Patents

Inibição da interação entre hif-1alfa e p300/cbp com hélices à base de substituintes de ligação de hidrogênio

Info

Publication number
BRPI0919414A2
BRPI0919414A2 BRPI0919414A BRPI0919414A BRPI0919414A2 BR PI0919414 A2 BRPI0919414 A2 BR PI0919414A2 BR PI0919414 A BRPI0919414 A BR PI0919414A BR PI0919414 A BRPI0919414 A BR PI0919414A BR PI0919414 A2 BRPI0919414 A2 BR PI0919414A2
Authority
BR
Brazil
Prior art keywords
hif
interaction
peptides
1alfa
cbp
Prior art date
Application number
BRPI0919414A
Other languages
English (en)
Inventor
Arora Paramjit
Olenyuk Bodgan
N Chapman Ross
Henchey Laura
M Block Katherine
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of BRPI0919414A2 publication Critical patent/BRPI0919414A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

PEPTÍDEOS PARA A INTERAÇÃO ENTRE HIF-1ALFA E P300/CBP E USOS DOS MESMOS. A presente invenção refere-se a peptídeos tendo uma ou mais (Alfa)-hélices estáveis, internamente restritas e que incluem uma sequência que imita pelo menos uma porção do domínio de transativação C-terminal de HIF-1(Alfa). Também são descritas composições farmacêuticas contendo estes peptídeos e métodos de usar estes peptídeos, por exemplo, para reduzir transcrição de genes, tratar ou prevenir distúrbios mediados por interação de HIF-1(Alfa) com a proteína de ligação a CREB e/ou p300, reduzir ou prevenir angiogênese em um tecido, induzir apoptose, diminuir sobrevivência e/ou proliferação e identificar ligantes potenciais de proteína de ligação a CREB e /ou p300.
BRPI0919414A 2008-09-18 2009-09-18 Inibição da interação entre hif-1alfa e p300/cbp com hélices à base de substituintes de ligação de hidrogênio BRPI0919414A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9819308P 2008-09-18 2008-09-18
PCT/US2009/057592 WO2010033879A2 (en) 2008-09-18 2009-09-18 Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices

Publications (1)

Publication Number Publication Date
BRPI0919414A2 true BRPI0919414A2 (pt) 2017-07-11

Family

ID=42040175

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919414A BRPI0919414A2 (pt) 2008-09-18 2009-09-18 Inibição da interação entre hif-1alfa e p300/cbp com hélices à base de substituintes de ligação de hidrogênio

Country Status (9)

Country Link
US (1) US9399666B2 (pt)
EP (1) EP2344520B1 (pt)
JP (2) JP2012503013A (pt)
CN (1) CN102216322A (pt)
AU (1) AU2009293020A1 (pt)
BR (1) BRPI0919414A2 (pt)
CA (1) CA2737614A1 (pt)
ES (1) ES2446249T3 (pt)
WO (1) WO2010033879A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510236A (ja) * 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法
BRPI0720306A2 (pt) 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
CA2678941C (en) 2007-02-23 2018-11-27 Aileron Therapeutics, Inc. Triazole macrocycle systems
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
WO2010033879A2 (en) 2008-09-18 2010-03-25 New York University Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices
CN102482336B (zh) 2008-09-22 2015-05-06 爱勒让治疗公司 拟肽大环化合物
CA2743177A1 (en) 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
AU2010204648B2 (en) 2009-01-14 2016-09-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
US8511577B2 (en) 2011-02-24 2013-08-20 Nest Labs, Inc. Thermostat with power stealing delay interval at transitions between power stealing states
ES2586411T3 (es) 2011-03-04 2016-10-14 New York University Macrociclos sustitutos de enlace de hidrógeno como moduladores de Ras
EP2768518A4 (en) 2011-10-18 2015-05-27 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
CN104066435A (zh) 2011-12-21 2014-09-24 纽约大学 蛋白水解抗性的氢键替代螺旋
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
US9605026B2 (en) * 2013-01-19 2017-03-28 New York University Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation
CN105246481A (zh) * 2013-01-19 2016-01-13 纽约大学 用于p53再活化的低聚氧代哌嗪
WO2015034932A1 (en) * 2013-09-03 2015-03-12 New York University INHIBITING INTERACTION BETWEEN HIF-1αAND P300/CBP WITH HYDROGEN BOND SURROGATE-BASED HELICES
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
KR102034243B1 (ko) * 2016-07-05 2019-10-21 바스테라 주식회사 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6986881B1 (en) 1999-06-04 2006-01-17 Dana-Farber Cancer Institute, Inc. Identification of compounds that modify transcriptional responses to hypoxia
GB0211920D0 (en) * 2002-05-23 2002-07-03 Isis Innovations Ltd Assay
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
ITMI20042477A1 (it) 2004-12-23 2005-03-23 Cell Therapeutics Europe Srl Uso di antibiotici a strutura dichetoditiopiperazinica per la preparazione di composizioni farmaceutiche antiangiogeniche
KR100860060B1 (ko) * 2006-10-12 2008-09-24 한국과학기술연구원 ＨＩＦ-１α Ｃ-말단 펩타이드와 ＣＢＰ 또는 ｐ３００단백질과의 결합을 정량분석하는 방법 및 상기 방법을이용한 단백질 복합체 형성을 저해하는 억제제의 스크리닝방법
WO2010033879A2 (en) 2008-09-18 2010-03-25 New York University Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices
CA2737916A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles

Also Published As

Publication number Publication date
EP2344520A4 (en) 2012-03-14
JP2012503013A (ja) 2012-02-02
US20110245175A1 (en) 2011-10-06
CN102216322A (zh) 2011-10-12
WO2010033879A2 (en) 2010-03-25
AU2009293020A1 (en) 2010-03-25
EP2344520A2 (en) 2011-07-20
JP2015061833A (ja) 2015-04-02
EP2344520B1 (en) 2013-11-13
ES2446249T3 (es) 2014-03-06
US9399666B2 (en) 2016-07-26
WO2010033879A3 (en) 2010-07-15
CA2737614A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
Shah et al. Cdk5 activity in the brain–multiple paths of regulation
WO2010033879A3 (en) Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices
UY31067A1 (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
Ip et al. Cycloastragenol is a potent telomerase activator in neuronal cells: implications for depression management
Leucht et al. The PANSS should be rescaled
Maddox et al. Epigenetic alterations in the lateral amygdala are required for reconsolidation of a Pavlovian fear memory
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
Ferraguti et al. Nerve growth factor and the role of inflammation in tumor development
Palmeri et al. Salidroside, a bioactive compound of rhodiola rosea, ameliorates memory and emotional behavior in adult mice
Teo et al. Brain beta-catenin signalling during stress and depression
CO2021001472A2 (es) Inhibidores de transglutaminasa 2 (tg2)
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
BRPI0508931A (pt) ácido nucleico isolado, composição farmacêutica e usos de uma quantidade eficaz de um primeiro ligante de ácido nucleico
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
BRPI0606256A2 (pt) inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos
BR112015023386A8 (pt) composições e métodos para alterar os níveis de colesterol.
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
UY38740A (es) Mutantes de fgf21 y usos del mismo
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
DK1766077T3 (da) Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
X. Sureda et al. Antiapoptotic drugs: a therapautic strategy for the prevention of neurodegenerative diseases
BR112012025592A2 (pt) moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2532 DE 16-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.